Skip to main content

Advertisement

Table 3 Mean percentage (± SD) of positive immunohistochemically stained cells (IGF-1R and β-catenin) and mean SCORE results (ER, PR and PAX-2) in patient subgroups

From: Does Metformin affect ER, PR, IGF-1R, β-catenin and PAX-2 expression in women with diabetes mellitus and endometrial cancer?

  PR score ER score PAX-2 score IGF-1R β-catenin (membranous)
EC + diabetes (n = 48) 6.85 ± 1.76 6.91 ± 1.51 3.58 ± 2.42 36.79 ± 26.73 86.87 ± 19.17
M in mono- and polytherapy (n = 32) 6.78 ± 2.01 6.71 ± 1.67 3.37 ± 2.41 36.59 ± 24.49 83.75 ± 21.28
M in monotherapy (n = 22) 6.86 ± 1.83 6.77 ± 1.15 3.5 ± 2.64 36.41 ± 26.16 84.54 ± 20.23
I + SD (n = 16) 7.0 ± 1.15 7.31 ± 1.07 4.37 ± 2.02 37.18 ± 31.72 93.12 ± 12.36
I in monotherapy (n = 10) 7.1 ± 1.28 7.8 ± 0.42 4.2 ± 2.34 33.5 ± 28.96 97.0 ± 6.32
Control (n = 38) 6.39 ± 2.23 6.28 ± 2.17 3.34 ± 2.31 18.29 ± 27.27 87.5 ± 24.40
  1. EC- endometrial cancer, M- metformin, I- insulin, SD- sulfonylurea derivatives, I + SD- Due to small number of patients receiving sulfonylurea derivatives in monotherapy (n = 6) we have analyzed this subgroup together with patients treated with insulin.